Note 5 - Acquisition of EGEN, Inc. (Details) - USD ($)				1 Months Ended	6 Months Ended		12 Months Ended
	Aug. 02, 2016	Dec. 31, 2014	Jun. 10, 2014	Jun. 20, 2014	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015		Dec. 31, 2014	Jun. 09, 2014
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred									$ 13,878,204
Business Combination, Acquisition Related Costs									$ 1,385,263
EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Consideration Transferred				$ 27,600,000			$ 27,578,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				30,400,000			$ 30,400,000
Payments to Acquire Businesses, Gross				$ 3,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)				2,712,188			670,070		670,070
Business Combination, Consideration Transferred, Liabilities Incurred		$ 13,700,000		$ 13,900,000	$ 13,700,000		$ 13,878,000	[1]
Fair Value, Option, Changes in Fair Value, Gain (Loss)							13,900,000		$ 13,700,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability							257,702		$ 213,949
Goodwill, Acquired During Period				2,000,000
Business Combination, Acquisition Related Costs						$ 1,385,263
EGEN, Inc. [Member] | Hercules Credit Agreement [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Payments to Acquire Businesses, Gross			$ 3,000,000
Loans Payable										$ 5,000,000
EGEN, Inc. [Member] | In Process Research and Development [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Finite-lived Intangible Assets Acquired						$ 25,800,000
EGEN, Inc. [Member] | Maximum [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Consideration Transferred				$ 44,400,000
EGEN, Inc. [Member] | Scenario, Forecast [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)	670,070
EGEN, Inc. [Member] | Ovarian Cancer Study Milestone [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							12,400,000
EGEN, Inc. [Member] | Glioblastoma Multiforme Brain Cancer Study Milestone [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							12,000,000
EGEN, Inc. [Member] | TheraSilence Technology Milestone [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							$ 6,000,000

[1] The total aggregate purchase price for the EGEN Acquisition included potential future Earn-Out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-Out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone payments will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statement. As of December 31, 2015 and 2014, the Company fair valued these milestones at $13.9 million and $13.7 million, respectively. During 2015, the Company recognized a non-cash charge of $257,702 as a result of the change in the fair value of these milestones from December 31, 2014 and recognized a non-cash benefit of $213,949 during 2014 as a result of the change in the fair value of these milestones from June 20, 2014.